Liposomal bupivacaine-containing versus standard bupivacaine interscalene nerve blocks in shoulder surgery: A systematic review and meta-analysis
Shoulder & Elbow · 5 Nov 2026
† Impact is the editorial-priority score. All scores are out of 100. Clinical is how far this paper should move patient care if its methods hold up; it does not measure the size of a treatment benefit.
Why it matters
Liposomal bupivacaine costs about $330 more per dose, and this review suggests its added analgesic benefit in interscalene blocks is too small to matter clinically for most shoulder surgery patients.
The evidence
This meta-analysis pooled four randomised trials (181 patients per arm) comparing interscalene nerve blocks containing liposomal bupivacaine with standard bupivacaine hydrochloride blocks for shoulder arthroscopy and arthroplasty. Liposomal bupivacaine lowered pain scores slightly at 24 hours (mean difference -0.6 on a 0-10 scale, 95% CI -0.9 to -0.3) and 72 hours (-0.4, 95% CI -0.5 to -0.3), but both differences fell below the roughly 1.0 to 1.5 point minimal clinically important difference the authors cite, and opioid use did not differ significantly. The 24-hour estimate had very high heterogeneity (I2 = 92.5%), and evidence certainty was low to moderate.
A coherent primary effect estimate is unavailable. Clinical relevance does not estimate treatment benefit.
Why this rigour score?
Meta-analysis of RCTsDesign starting point: 60.8
Raised the score
- Pools randomised trials+5.1
- Compared against current standard of care+3.4
Lowered the score
No negative adjustments recorded.
Score capped at 64. A critical methodological failure for a review.
Methods at a glance
Recorded assessment- Comprehensive literature searchMet
- Risk of bias assessedMet
- Bias considered in synthesisMet
- Publication bias assessedMet
- Study exclusions justifiedMet
- Prospective registrationNot met
Not reported does not mean not done. Checks have different weights; this is not a count of boxes ticked.
See the full score breakdown
- Study design starting point
- 60.8
- Compared against current standard of care
- +3.4
- Pools randomised trials
- +5.1
- Comprehensive literature search
- +3.4
- Risk of bias assessed in the included studies
- +3.4
- Risk of bias carried into the synthesis
- +2.5
- Excluded studies listed and justified
- +1.7
- Publication bias assessed
- +2.5
- Methodological cap
- −18.9
- Final rigour score rounded
- 64 / 100
Study design sets the starting point and a ceiling of 96. Recorded methods then adjust the score. Points are shown to one decimal place; the final score uses unrounded values.
Checklist from the stored appraisal. “Not met” describes the recorded criterion; it does not always produce a deduction. This overview supports reading the full study.
How the clinical score was reached
The question: 8/9. Three judgements of how much it matters to patients, which decision it informs and how closely it fits their care.
Patient consequence: moderate (2/3). A patient-experienced outcome of real but smaller or shorter-lived importance: early pain or function, speed of recovery, return to sport or work, minor complications, satisfaction, or a validated score at a short time point.
Decision relevance: high (3/3). The study compares the actual options a clinician chooses between (or a whole strategy), and its primary result directly indicates which to choose, or that they are interchangeable. A clinician could act on it without a further translation step.
Applicability: moderate (3/3). A recognisable practice population, but with a notable restriction: narrow eligibility, a single expert surgeon or centre, or an unusual protocol that would need adapting. Applicability only subtracts for a real mismatch, so moderate counts in full.
What it found: Points one way (×0.86). A verdict without a usable interval, a clear result from a trial the paper itself calls underpowered, or a review whose certainty is low or unrated.
The design ceiling: 98. The most a meta-analysis of rcts can score here, however relevant its question and clear its answer.
Clinical = 98 × 8/9 × 0.86 = 75.
For journal club
1.If liposomal bupivacaine gives only a sub-MCID pain reduction, are there specific shoulder patients (for example opioid-tolerant patients or outpatient arthroplasty) in whom its extended duration could still justify the cost?
2.How should you counsel a patient about rebound pain as a standard interscalene block wears off, and what multimodal or adjunct strategies could replace a pricier long-acting formulation?
Original publication title
Liposomal bupivacaine-containing versus standard bupivacaine interscalene nerve blocks in shoulder surgery: A systematic review and meta-analysis